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The toxicity of benzene is generally
thought to be mediated by metabolites
formed in the liver (1,2). Benzene is
metabolized in vivo to ring-hydroxylated
intermediates as well as trans,trans-mucon-
ic acid (muconic acid, MA; Table 1), a
ring-opened intermediate (2). We have
hypothesized that reactive ring-opened
intermediates play an important role in
benzene toxicity (3). Our laboratory has
identified one such compound, the dialde-
hyde trans,trans-muconaldehyde (muconal-
dehyde, MUC; Table 1), in mouse-liver
microsomal incubations of benzene (4).
Muconaldehyde is a potent electrophile
(5), a cross-linking agent (6), and is hema-
totoxic when injected in mice (7). Mu-
conaldehyde has not been directly detected
in animals dosed with benzene, presumably
due to its reactivity. In vitro, MUC is
metabolized to a number of oxidized and
reduced products of which MA and 6-
hydroxy-trans,trans-hexadienoic acid
(HHA, Table 1) are stable end products
(8,9). We previously established that
MUC is metabolized in vivo to MA (10).
We undertook the present studies to iden-
tify HHA in the urine ofCD-I mice treat-
ed with MUC and benzene to provide fur-
ther evidence for the intermediacy of
MUC in the metabolism of benzene in
vivo.
A procedure previously used in this lab-
oratory for extracting and analyzing MA in
mouse urine (10J was modified to simulta-
neously analyze HHA and MA. We added
three volumes of methanol to one volume
of urine. After cooling at -20°C for 2-3
hr, samples were spun in a microcentrifuge
for 10 min and the pellet was discarded.
We evaporated methanol from the super-
natant at 37°C using a nitrogen stream and
acidified the remaining sample to pH
2.5-3.0 with concentrated hydrochloric
acid. Samples were extracted six times
with two volumes of diethyl ether. We
pooled the ether fractions, evaporated the
ether at 37°C using a nitrogen stream, and
redissolved the residues in methanol for
analysis. Samples (10-20 ,ul) were ana-
lyzed for MA and HHA by analytical C18
reverse-phase HPLC using a flow rate of
1.0 ml/min, and absorbance was moni-
tored at 260 nm. We determined theXmmax
ofchromatogram peaks using a diode-array
detector. Samples were eluted isocratically
using 10% methanol and 90% aqueous
acetic acid (1%). Under these conditions
HHA eluted between 9 and 10 min, and
MA eluted between 13 and 14 min. We
also reacted extracts with a diethyl ether
solution of diazomethane (11) to convert
HHA to the more hydrophobic methyl
ester, Me-HHA (Table 1). We analyzed
the methylated extracts by reverse-phase
HPLC using 13% methanol and 87%
aqueous acetic acid (1%) as the eluant.
Under these conditions, Me-HHA eluted
between 29 and 31 min.
We validated quantification ofMA and
HHA by this method using spiked mouse
urine. [HHA was prepared by from 6-oxo-
trans,trans-hexadienoic acid (5) by reduc-
tion with sodium borohydride (9)]. Ex-
traction, HPLC analyses, and peak integra-
tion of MA/HHA spiked mouse urine
indicated a linear response in unmethylated
extracts for MA in the range of5-50 pg/ml 2 urine (r = 0.956) and HHA in the range
2 of4-10 pg/ml urine (r = 0.975). Below 4
pg/ml, quantification of HHA was com-
promised due to the presence of endoge-
nous peaks present in some urines eluting
close to HHA. Recoveries ofboth MA and
HHA were 40% after the extraction.
Reproducibility was 18% relative standard
deviation (RSD) for HHA and 19% RSD
for MA at 10 pg/ml (N=6). Diode-array
spectra of peaks coeluting with HHA and
MA exhibited maxima in the range of
258-259 nm and 264-265 nm, respective-
ly, as did the chromatographed standards
ofHHA and MA in methanol. In methy-
lated spiked-urine extracts, Me-HHA
exhibited diode-array spectral maxima in
the range of 260-264 nm. Dose response
of Me-HHA integration was linear from 1
to 10 pg HHA/ml (r2 = 0.964). Methyl-
ation ofHHA in urine extracts was quanti-
tative.
We treated male CD-1 mice, 10 weeks
old, intraperitioneally with benzene,
We studied the in vivo metabolism of ben-
zene in ic t.o ring-op punds
excete inurie~ aleC-D-I4 mieWere
treated inrper..tl..biteall wihbezn
mg/kg) or trant conal..Tdehyde
(MUC 4 mic o-
ic metoeofbenzene. Uriine..collected
over 24 hr .was xracted andanalyzed by
HPLC witha diode-arr.ay detectorn..d by
*trani~.rrauu-2,4-hedienoic acid, was detect-
ed in.urine f ic treate.d wit eiter ben- *zene or|; MUC...I. We. identi ie new '3t ated tcsanad in un'e -wezmtedthylatfed aend
here are t with the.it.e.r iy of
MUC in th.e in: viw.meta;bolism ofbzenace
to ring-opened i.. K. y was: ben-
. ...... m e t ..ro
eriaryliteiboie benvi
Heathmer0:310-12(19 14~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~1
[14C]benzene, or MUC. MUC was cus-
tom-synthesized by Calbiochem (San
Diego, CA) by a procedure of Kossmehl
and Bohn (12) previously used in our lab-
oratory (3). One day before treatment, we
transferred animals to metabolism cages
(three mice per cage) and collected urine
over 24 hr in traps containing 2 ml of
0.2% (w/v) ascorbic acid. These urines
served as no-treatment controls. We trans-
ferred each group ofmice to clean metabo-
lism cages and injected them intraperi-
toneally with 0.1 ml of corn oil solutions
containing either benzene (110, 220, or
440 mg/kg), [ 4C]benzene (220 mg/kg),
or MUC (4 mg/kg). The urine from each
treated group was collected over 24 hr in
traps containing 2 ml 0.2% ascorbic acid.
We determined total urine volume and
stored samples at -70°C until analysis.
Scintillation counting of aliquots of urine
collected from [14C]benzene-treated mice
indicated that at least 68% ofadministered
label was excreted in the urine after 24 hr.
After extraction, 15% of this radioactivity
partitioned into the ether phase. One-half
of the ether extract from each urine was
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subjected to methylation using diazo-
methane, and extracts were analyzed by
HPLC and, for radioactive samples, scintil-
lation counting. We spiked a portion of
the extracts from unmethylated samples
with MA and reanalyzed HHA to establish
coelution of peaks. Similarly, portions of
extracts from methylated samples were
spiked with Me-HHA and reanalyzed.
Figure IA shows the chromatogram of
extracted urine from mice treated intra-
peritioneally with 220 mg/kg [ 4C]ben-
zene, which exhibits the presence of two
peaks eluting at 9.39 min and 13.39 min.
These peaks co-chromatographed with
HHA and MA, respectively, and exhibited
diode-array spectra identical to the authen-
tic compounds (Xmax: HHA, 259 nm; MA
264 nm). Radioactive peaks were also
observed in the radiochromatogram at
retention times of HHA and MA (Fig.
IA), indicating the presence of benzene
metabolites. Corresponding HHA and
MAcoeluting peaks were also seen in chro-
matograms of urine extracts from mice
treated with 110, 220, and 440 mg/kg
benzene and 4 mg/kg muconaldehyde.
These peaks were absent in chromatograms
from extracted urines ofthe same mice col-
lected 24 hr before benzene treatment
(data not shown).
The chromatogram of a methylated
ether extract from urine of mice treated
with 220 mg/kg [ 4C]benzene (Fig. iB)
reveals the presence of a compound that
coelutes with HHA methyl ester (tR = 29.3
min) and exhibits a diode-array spectrum
consistent with Me-HHA (,max = 259
Table 1. Structure of benzene metabolites
X H
H
H
H y
Compound X Y
MA C02H C02H
MUC CHO CHO
HHA CH20H C02H
Me-HHA CH20H C02Me
HAl CH20H CHO
Ml C02H CHO
Abbreviations: MA, trans,trans-muconic acid;
MUC, trans,trans-muconaldehyde; HHA, 6-hy-
droxy-trans,trans-2,4-hexadienoic acid; Me-HHA,
6-hydroxy-trans,trans-2,4-hexadienoic acid methyl
ester; Me-MA, trans,trans-muconic acid dimethyl
ester; HAl, 6-hydroxy-trans,trans-2,4-hexadienal;
AAl,6-oxo-trans,trans-hexadienoic acid.
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Figure 1. Chromatograms and radiochromatograms of (A) unmethylated and (B) methylated urine
extracts from mice treated with [14CJbenzene. See text for details of methods. The unmethylated and
methylated extract were each dissolved in 200 0 of methanol, and 100J was analyzed on reverse-phase
HPLC using elution with 1% acetic acid:methanol (unmethylated, 90:10; methylated, 87:13). Fractions of
eluent (unmethylated, 0.3 ml; methylated, 0.5 ml) were quantitfied by scintillation counting. (Line)
absorbance; (vertical bar) dpm.
nm). (A shoulder on the Me-HHA peak
in the chromatogram shown in Figure 1B
was not present in chromatograms of
methylated urine extracts from mice treat-
ed with unlabeled benzene). A radioactive
peak also coeluting with Me-HHA was
observed in the radiochromatogram (Fig.
1B). Total counts of radioactivity coelut-
ing with HHA in the unmethylated extract
(Fig. IA) and Me-HHA in the methylated
extract (Fig. 1B) were the same. A peak
coeluting with unmethylated HHA is
absent from the chromatogram and radio-
chromatogram (as is MA). The corre-
sponding coeluting peak was also seen in
chromatograms of methylated urine ex-
tracts from mice treated with 110, 220,
and 440 mg/kg benzene and 4 mg/kg
muconaldehyde and was absent in chro-
matograms from methylated urine extracts
of the same mice collected 24 hr before
benzene treatment (data not shown). The
dimethyl ester of muconic acid (Me-MA;
Table 1) was also present in methylated
extracts ofurines from benzene and MUC-
treated animals (data not shown). This
compound, being more hydrophobic than
Me-HHA, did not elute under the HPLC
conditions described.
The excretion of urinary MA and
HHA by benzene- and MUC-treated mice
is summarized in Table 2. Muconic acid
was excreted in significantly greater
amounts than HHA in MUC-treated mice
and in benzene-treated animals at all doses.
Ratios ofHHA to MA at all benzene doses
in this study (7.1, 15.3, and 11.1) were
similar to the HHA to MA ratio obtained
after MUC administration (5.2; Table 2).
Trans,trans-muconic acid was first defi-
nitely identified as an in vivo metabolite of
benzene in the urine ofrabbits (13). HHA
is the second ring-opened metabolite of
benzene that has been detected in vivo.
The evidence for identification of this
compound is based on the following: 1)
the presence of a compound in extracts of
urine from benzene- and MUC-treated
mice that coelutes with authentic HHA on
reverse-phase HPLC and which has a UV
diode-array spectrum consistent with
HHA. This compound is absent in ex-
tracts of urine obtained from the same
mice immediately before treatment; 2) the
presence of a peak in methylated urine
extracts from benzene- and MUC-treated
mice that coelutes with authentic HHA
methyl ester. This compound has a UV
diode-array spectrum consistent with
HHA methyl ester and is not present in
control urine extracts; 3) coelution of
radioactivity with HHA and Me-HHA in
extracted urine (unmethylated and methy-
lated) from mice exposed to [14C]benzene.
Total radioactive counts eluting with
HHA and Me-HHA were the same in
unmethylated and methylated extracts.
Detection of HHA as a metabolite of
MUC in vivoextends observations made in
vitro (8,9). Detection ofHI-IA in urine of
benzene-treated animals is consistent with
the hypothesis that benzene is metabolized
in vivo to ring-opened metabolites via
MUC (Fig. 2). Similar MA:HHA ratios in
benzene versus MUC-treated animals
strengthen this hypothesis. MUC is a
benzene metabolite in mouse microsomal
,HHA
Benzene >MUC
aMA
Figure 2. Possible metabolism of benzene to 6-
hydroxy-trans,trans-hexadienoic acid (HHA) and
trans,trans-muconic acid (MA) via trans,trans-
muconaldehyde (MUC).
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Table 2 Excretion of muconic acid (MA) and 6-hydroxy-trans,trans-2,4-hexadienoic acid (HHA) by CD-1
micetreated with benzene or trans,trans-muconaldehyde (MUC)
Mean ±SE excreted in urine
(pnmol/kg; n= 3)
pmol/kg Injected
Compound (mg/kg) MA HHA
Benzene 1500 12.2±0.2 1.73±0.16
(110)
Benzene 2800 36.6±3.7 2.31 ±0.27
(220)
Benzene 5600 16.9±1.5 1.52±0.06
(440)
MUC 36 8.1 ±0.8 1.56±0.51
(4)
Mice, three per cage, one cage per dose, were treated intraperitoneally with compound dissolved in
corn oil. Urines were collected for 24 hr and volume was determined. Portions of the urines were
extracted and analyzed as described in the text. Urinary MA concentration was calculated from the
integrated area ofthe MA coeluting peak in unmethylated urine extracts using a standard curve generat-
ed by extraction and analysis of mouse urine spiked with MA. Urinary HHA concentration was
determined from the integrated area ofthe Me-HHA coeluting peak in methylated urine extracts using a
standard curve generated by extraction, methylation, and analysis of mouse urine spiked with HHA.
incubations, but its reactivity probably pre-
cludes its direct detection in vivo.
Although MUC is a potential interme-
diate in the metabolic conversion of ben-
zene to ring-opened products, other com-
pounds may also be considered. Conver-
sion of MA to HHA is unlikely because
carboxylic acids are not reduced by dehy-
drogenases. The mixed-hydroxy aldehyde
analogue of MUC (HAl; Table 1) is con-
verted to HHA byyeast aldehyde dehydro-
genase (8) and mouse liver cytosol (9).
However, HAl is not converted to MA in
these systems (8,9). Another MUC ana-
logue, the carboxylic acid aldehyde (AAI;
Table 1) is metabolized to MA and to a
small amount of HHA by mouse liver
cytosol (9). In incubations ofNADH-for-
tified alcohol dehydrogenase, the car-
boxylic acid aldehyde is not reduced to
HHA (8). Thus, HAl, as well as MUC, is
a common precursor of HHA and MA in
vitro. However, there is no evidence to
rule out either ofthese compounds as pre-
cursors of HHA and MA formed from
benzene in vivo.
In conclusion, we have established the
presence ofa novel ring-opened metabolite
in the urine ofbenzene-treated mice. This
mnetabolite is also present in the urine of
mice after treatment with muconaldehyde.
The formation of HHA as an in vivo
metabolite of MUC confirms results ob-
tained in vitro (9). The formation of this
compound from benzene in vivo provides
further evidence for the intermediacy of
MUC in benzene metabolism. The detec-
tion and quantification of HHA in the
urine of humans with known exposure to
benzene is a goal of our research, particu-
larly in view of recent attempts to use
human urinary muconic acid as a biologi-
cal marker relevant to the risk assessment
ofbenzene (14).
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